Additional Information
Book Details
Abstract
This issue of Medical Clinics of North America provides the latest essential updates on COPD. The following topics are covered: pathobiological mechanisms; genes and the disease (alpha-l-antitrypsin); the environment, phenotype, and comorbidity; the role and potential of imaging; pulmonary function and its importance; exercise in testing and therapy; patients’ perception and quality of life; exacerbations, causes, prevention, and treatment; an integrated approach to the medical treatment; meducal pneumoplasty, surgical resection, or lung transplant; and smoking cessation and environmental hygiene.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Medical Clinics of North America | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| Contributors | v | ||
| Preface | xi | ||
| Chapter 1. Chronic Obstructive Pulmonary Disease: A Worldwide Problem | 671 | ||
| EPIDEMIOLOGY | 672 | ||
| DEFINITION OF COPD | 674 | ||
| RISK FACTORS | 674 | ||
| SPIROMETRY SCREENING | 675 | ||
| BURDEN OF COPD IN DEVELOPING COUNTRIES | 675 | ||
| FUTURE | 676 | ||
| ACKNOWLEDGMENTS | 676 | ||
| REFERENCES | 676 | ||
| Chapter 2. Pathobiologic Mechanisms of Chronic Obstructive Pulmonary Disease | 681 | ||
| INTRODUCTION | 681 | ||
| PHENOTYPES OF COPD | 682 | ||
| PROPERTIES OF CS | 683 | ||
| CYTOCHROME P-450 GENE EXPRESSION | 683 | ||
| PATHOBIOLOGIC MECHANISMS | 684 | ||
| DUTCH, BRITISH, AND AMERICAN HYPOTHESES | 688 | ||
| PROTEASE–ANTIPROTEASE HYPOTHESIS OF EMPHYSEMA | 689 | ||
| AUTOIMMUNE HYPOTHESIS OF COPD | 689 | ||
| GWAS AND COPD | 690 | ||
| SUMMARY | 691 | ||
| REFERENCES | 691 | ||
| Chapter 3. Genes and Chronic Obstructive Pulmonary Disease | 699 | ||
| COPD DUE TO SEVERE AAT DEFICIENCY | 700 | ||
| GENETICS OF COPD UNRELATED TO SEVERE AAT DEFICIENCY | 702 | ||
| SUMMARY | 707 | ||
| REFERENCES | 707 | ||
| Chapter 4. Contribution of the Environment and Comorbidities to Chronic Obstructive Pulmonary Disease Phenotypes | 713 | ||
| ENVIRONMENT | 714 | ||
| HOST FACTORS | 715 | ||
| COMORBIDITIES | 716 | ||
| PROGRESS IN DISEASE PHENOTYPES | 721 | ||
| SUMMARY | 721 | ||
| REFERENCES | 722 | ||
| Chapter 5. The Role and Potential of Imaging in COPD | 729 | ||
| INTRODUCTION | 729 | ||
| CT | 730 | ||
| MRI | 735 | ||
| PET | 737 | ||
| OCT | 737 | ||
| REFERENCES | 738 | ||
| Chapter 6. The Importance of the Assessment of Pulmonary Function in COPD | 745 | ||
| INTRODUCTION | 745 | ||
| ROLE OF SPIROMETRY IN THE DIAGNOSIS OF COPD | 745 | ||
| INTRODUCTION TO PULMONARY FUNCTION TESTING | 746 | ||
| DIAGNOSIS OF COPD BASED ON SPIROMETRY | 747 | ||
| DIFFERENTIATING COPD FROM ASTHMA WITH BRONCHODILATOR REVERSIBILITY TESTING | 748 | ||
| QUANTIFYING COPD SEVERITY WITH SPIROMETRY | 748 | ||
| ROLE OF SPIROMETRY IN THE MANAGEMENT OF COPD | 749 | ||
| SUMMARY | 751 | ||
| REFERENCES | 751 | ||
| Chapter 7. Role of Exercise in Testing and in Therapy of COPD | 753 | ||
| INTRODUCTION | 753 | ||
| MODALITIES OF EXERCISE TESTING | 754 | ||
| SUMMARY | 763 | ||
| REFERENCES | 763 | ||
| Chapter 8. Defining Patient-Reported Outcomes in Chronic Obstructive Pulmonary Disease: The Patient-Centered Experience | 767 | ||
| INTRODUCTION | 767 | ||
| DEFINING THE PATIENT EXPERIENCE AND PATIENT-REPORTED OUTCOMES | 768 | ||
| DEFINING AND MEASURING HRQOL | 768 | ||
| ACCOUNTING FOR PATIENT PREFERENCES | 770 | ||
| INTERPRETING HRQOL MEASURES | 773 | ||
| PREDICTIVE MODELS | 773 | ||
| HRQOL IN COPD | 774 | ||
| ASSOCIATIONS OF PROs WITH PHYSIOLOGIC MEASURES | 774 | ||
| THE IMPACT OF COPD ON PROs | 775 | ||
| INTERVENTIONS THAT AFFECT HRQOL | 776 | ||
| SUMMARY | 782 | ||
| REFERENCES | 782 | ||
| Chapter 9. COPD Exacerbations: Causes, Prevention, and Treatment | 789 | ||
| FREQUENT EXACERBATOR PHENOTYPE | 789 | ||
| VIRAL INFECTIONS | 790 | ||
| BACTERIAL INFECTIONS | 792 | ||
| ENVIRONMENTAL FACTORS | 795 | ||
| EXACERBATION PREVENTION | 795 | ||
| PHARMACOLOGIC THERAPIES | 796 | ||
| NONPHARMACOLOGIC THERAPIES | 799 | ||
| SUMMARY | 803 | ||
| REFERENCES | 803 | ||
| Chapter 10. An Integrated Approach to the Medical Treatment of Chronic Obstructive Pulmonary Disease | 811 | ||
| INTRODUCTION | 811 | ||
| EVALUATING COPD SEVERITY IN CLINICAL PRACTICE: MORE THAN THE FORCED EXPIRATORY VOLUME IN THE FIRST SECOND OF EXPIRATION | 812 | ||
| COPD MEDICAL THERAPY IN CONTEXT | 816 | ||
| SUMMARY | 821 | ||
| REFERENCES | 822 | ||
| Chapter 11. Medical Pneumoplasty, Surgical Resection, or Lung Transplant | 827 | ||
| INTRODUCTION | 827 | ||
| PATHOPHYSIOLOGIC BASIS FOR LUNG VOLUME REDUCTION | 827 | ||
| MEDICAL PNEUMOPLASTY | 828 | ||
| SURGICAL RESECTION | 834 | ||
| SUMMARY | 845 | ||
| REFERENCES | 845 | ||
| Chapter 12. Smoking Cessation and Environmental Hygiene | 849 | ||
| CIGARETTE SMOKING AND SMOKING CESSATION | 850 | ||
| SMOKING CESSATION TECHNIQUES | 850 | ||
| NONSMOKING RISK FACTORS IN COPD | 852 | ||
| OUTDOOR AIR POLLUTION | 853 | ||
| BIOMASS SMOKE | 855 | ||
| OCCUPATIONAL EXPOSURES | 856 | ||
| AMATEUR EXPOSURES | 857 | ||
| MARIJUANA AND OTHER INHALED ILLICIT AGENTS | 857 | ||
| SUMMARY | 858 | ||
| REFERENCES | 858 | ||
| Index | 869 |